ACCRETION PHARMA LIMITED Fair Value
ACCPL · Healthcare · Current price ₹165.65
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹191 | 44% ROE fading to 12% over ~10 yrs, on ₹49 book |
| Relative P/E | ₹252 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹96 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is ACCRETION PHARMA LIMITED undervalued?
DocStoX estimates the fair value of ACCRETION PHARMA LIMITED at ₹193 per share, versus the current market price of ₹166. That puts the stock about +16.7% below our fair-value estimate, which we read as "Fairly Valued". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹191), Relative P/E (₹252), Graham floor (₹96). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹96 (bear) to ₹193 (base) to ₹252 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ACCRETION PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.